- Home
- SITC vs AMRN Comparison
SITC vs AMRN Comparison
Compare SITC & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SITC
- AMRN
- Stock Information
- Founded
- SITC 1965
- AMRN 1989
- Country
- SITC United States
- AMRN Ireland
- Employees
- SITC N/A
- AMRN N/A
- Industry
- SITC Real Estate Investment Trusts
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- SITC Real Estate
- AMRN Health Care
- Exchange
- SITC Nasdaq
- AMRN Nasdaq
- Market Cap
- SITC 391.8M
- AMRN 338.7M
- IPO Year
- SITC 1993
- AMRN 1993
- Fundamental
- Price
- SITC $7.30
- AMRN $16.30
- Analyst Decision
- SITC Hold
- AMRN Strong Sell
- Analyst Count
- SITC 4
- AMRN 1
- Target Price
- SITC $12.63
- AMRN $12.00
- AVG Volume (30 Days)
- SITC 1.1M
- AMRN 146.2K
- Earning Date
- SITC 11-05-2025
- AMRN 10-29-2025
- Dividend Yield
- SITC 79.04%
- AMRN N/A
- EPS Growth
- SITC N/A
- AMRN N/A
- EPS
- SITC 0.54
- AMRN N/A
- Revenue
- SITC $139,962,000.00
- AMRN $226,733,000.00
- Revenue This Year
- SITC N/A
- AMRN N/A
- Revenue Next Year
- SITC N/A
- AMRN N/A
- P/E Ratio
- SITC $13.32
- AMRN N/A
- Revenue Growth
- SITC N/A
- AMRN N/A
- 52 Week Low
- SITC $6.89
- AMRN $7.08
- 52 Week High
- SITC $16.51
- AMRN $20.90
- Technical
- Relative Strength Index (RSI)
- SITC 24.88
- AMRN 41.40
- Support Level
- SITC $6.89
- AMRN $15.11
- Resistance Level
- SITC $7.48
- AMRN $15.85
- Average True Range (ATR)
- SITC 0.19
- AMRN 0.95
- MACD
- SITC -0.09
- AMRN -0.31
- Stochastic Oscillator
- SITC 17.82
- AMRN 20.27
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.